First Manhattan’s Supernus Pharmaceuticals SUPN Stock Holding History

First Manhattan’s Portfolio SUPN Stock Details SUPN Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2020 Q3	–	Sell	-93,770	Closed	-$2.23M	–	1454
2020 Q2	$2.23M	Sell	93,770 -470,900	-83%	-$10.4M	0.01%	294
2020 Q1	$10.2M	Hold	564,670	–	–	0.07%	142
2019 Q4	$13.4M	Buy	+564,670	New	+$13.7M	0.07%	139

Other funds holding SUPN

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Armistice Capital New York $5.62B AUM 36.06% 1-Year Est. Return

Macquarie Group Sydney, NSW 2000, Australia $16.8B AUM 27.39% 1-Year Est. Return

Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return

Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

ACB

Aristotle Capital Boston Boston, Massachusetts $1.61B AUM 19.82% 1-Year Est. Return

GKIM

GW&K Investment Management Boston, Massachusetts $11.3B AUM 31.98% 1-Year Est. Return

RHJA

Rice Hall James & Associates San Diego, California $1.8B AUM 36.16% 1-Year Est. Return

First Manhattan's SUPN Position: Q3 2020 in Review

First Manhattan sold out of Supernus Pharmaceuticals (SUPN) in Q3 2020, closing a stake of 93,770 shares — an estimated $2.23M sold.

First Manhattan first reported a position in SUPN in Q4 2019 and held it in 3 quarters. The position peaked at $13.4M in Q4 2019. 209 funds tracked by Wall St. Rank hold SUPN as of Q3 2020.

First Manhattan reported no remaining Supernus Pharmaceuticals position as of Q3 2020 after selling out during the quarter.
First Manhattan sold 93,770 Supernus Pharmaceuticals shares in Q3 2020, an estimated $2.23M.
First Manhattan first reported a position in Supernus Pharmaceuticals in Q4 2019 and held it in 3 quarters.
First Manhattan's Supernus Pharmaceuticals position peaked at $13.4M in Q4 2019.
209 funds tracked by Wall St. Rank held Supernus Pharmaceuticals as of Q3 2020.

Based on First Manhattan's 13F filing for Q3 2020, filed 12 Nov 2020.